Clinical Trials in New York State

Showing 7661-7680 of 13,041 trials

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

NCT00577161

BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and reduced delayed cardiotoxicity in animal models compared to reference standards. This cytotoxic agent has structural similarities to mitoxantrone as well as general similarities to anthracyclines (such as the tricyclic central quinoid chromophore7). This phase III study will compare the efficacy and safety of the combination BBR 2778, fludarabine, and rituximab with the combination fludarabine and rituximab in patients with relapsed or refractory indolent non-Hodgkin's lymphoma.

Non-Hodgkin's Lymphoma

CTI BioPharmaStarted Sep 2007

Muscle Shoals, Alabama, United States • Oxnard, California, United States • Jefferson City, Missouri, United States +5 more locations

COMPLETEDNA81 miles

BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease

NCT02228564

Collect confirmatory evidence of the safety and effectiveness of the Balloon LIFESTREAM™ Stent Graft for the treatment of stenoses and occlusion in the iliac arteries.

Peripheral Artery DiseasePeripheral Vascular DiseaseArterial Occlusive Disease

C. R. Bard155 participantsStarted Sep 2014

Little Rock, Arkansas, United States • Orange, California, United States • Sacramento, California, United States +17 more locations

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease

Find Trials by Condition in New York State

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings

AMZ001 for the Treatment of Knee Osteoarthritis Symptoms

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Single Arm on the Tolerability of Weekly Nab-paclitaxel

A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

PAVES Benchmarking Pilot Study of Daily Disposable Contact Lenses

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias